Factors impacting unbound vancomycin concentrations in neonates and young infants
Vancomycin pharmacokinetic (PK) and pharmacodynamic (PD) data in neonates are based on total concentrations. However, only unbound vancomycin is pharmacologically active. The objective was to determine vancomycin protein binding and the covariates impacting unbound vancomycin concentration in neonates and young infants. In neonates and young infants to whom vancomycin was administered intermittently for medical indications, total and unbound vancomycin plasma concentrations were determined using LC-MS/MS. Sampling occurred randomly during vancomycin exposure, covering a broad range of concentrations. Impact of covariates on unbound vancomycin concentration was determined using linear regression. Significant results of the univariate regressions were entered in a stepwise multiple regression. Passing-Bablok regression and Bland-Altman were used to assess the difference between measured and calculated unbound vancomycin concentration. Thirty-seven samples in 33 patients (median (interquartile range) gestational age 35 (29–39) weeks) were collected. Median total and unbound vancomycin concentrations were 14.2 (7.4–20.6) and 13.6 (7.2–22.5) mg/L, respectively. Median unbound fraction was 0.90 (0.77–0.98). Multiple regression revealed total vancomycin concentration (β = 0.884, p < 0.001) and albumin (β = − 0.323, p = 0.007) as most important covariates of unbound vancomycin concentrations, with an R2 adjusted of 0.953 (p < 0.0001). Mean absolute difference between calculated and measured unbound vancomycin was − 0.008 (95% CI − 0.92–0.91) mg/L. The unbound vancomycin fraction in neonates is higher compared to that in children and adults, and total vancomycin concentration and albumin were the most important covariates of unbound vancomycin concentration. Integration of protein binding in future PK/PD analyses is appropriate to optimize vancomycin dosing and to determine population-specific vancomycin PD targets for neonates.
KeywordsNeonate Vancomycin Protein binding Unbound concentration
K. Allegaert has been supported by the Fund for Scientific Research, Flanders (Belgium) (FWO Vlaanderen), by a fundamental Clinical Investigatorship (1800214N). The research activities of A. Smits, S. Pauwels, and I. Spriet were supported by the Clinical Research and Education Council of the University Hospitals Leuven. The research was further facilitated by the “Agency for Innovation, Science and Technology in Flanders” (IWT) through the “SAFEDRUG” project (IWT/SBO 130033).
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflicts of interest.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed parental consent was obtained for all included participants.
Data availability statement
The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.
- 5.Bhongsatiern J, Stockmann C, Roberts JK, Yu T, Korgenski KE, Spigarelli MG, Desai PB, Sherwin CM (2015) Evaluation of vancomycin use in late-onset neonatal sepsis using the area under the concentration-time curve to the minimum inhibitory concentration >/=400 target. Ther Drug Monit 37:756–765Google Scholar
- 16.De Cock PA, Desmet S, De Jaeger A, Biarent D, Dhont E, Herck I, Vens D, Colman S, Stove V, Commeyne S, Vande Walle J, De Paepe P (2017) Impact of vancomycin protein binding on target attainment in critically ill children: back to the drawing board? J Antimicrob Chemother 72(3):801–804PubMedGoogle Scholar
- 30.Sinkeler FS, de Haan TR, Hodiamont CJ, Bijleveld YA, Pajkrt D, Mathot RA (2014) Inadequate vancomycin therapy in term and preterm neonates: a retrospective analysis of trough serum concentrations in relation to minimal inhibitory concentrations. BMC Pediatr 14:193CrossRefPubMedPubMedCentralGoogle Scholar
- 31.Antimicrobial wild type distribution of microorganisms. European Committee on Antimicrobial Susceptibility Testing. Data from the EUCAST MIC distribution website, last accessed 21–01-2018. http://mic.eucast.org/Eucast2/
- 33.European Committee on Antimicrobial Susceptibility Testing. Data from the EUCAST website, Rationale for the EUCAST vancomycin clinical breakpoints, last accessed 21–01-2018 http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Rationale_documents/Vancomycin_rationale_2.1
- 40.Stoll BJ, Hansen N, Fanaroff AA, Wright LL, Carlo WA, Ehrenkranz RA, Lemons JA, Donovan EF, Stark AR, Tyson JE, Oh W, Bauer CR, Korones SB, Shankaran S, Laptook AR, Stevenson DK, Papile LA, Poole WK (2002) Late-onset sepsis in very low birth weight neonates: the experience of the NICHD Neonatal Research Network. Pediatrics 110:285–291CrossRefPubMedGoogle Scholar